Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2022-08-03 Earnings Release
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Isofol tillkännager toplineresultat från fas III-studien AGENT - varken det primära eller det viktigaste sekundära effektmåtten uppnåddes
Earnings Release Classification · 100% confidence The document is a press release from Isofol Medical AB announcing the topline results of their Phase III AGENT study, stating that neither the primary nor the key secondary endpoints were met. It details the study, mentions the next steps involving regulatory dialogue, and announces an audiocast for investors and media to discuss the results. This structure—a formal announcement of clinical trial results, often including financial implications and scheduling a follow-up call—is characteristic of an Earnings Release (ER) or a general announcement related to financial performance/material events. Since the core content is the immediate release of key financial/clinical performance data (even if negative), it fits best under 'Earnings Release' (ER) as it is the initial public disclosure of period-defining results, even though it's a clinical trial result rather than quarterly financials. It is not a full Annual Report (10-K), a transcript (CT), or a dedicated Investor Presentation (IP). It is an immediate disclosure of material information. FY 2022
2022-08-03 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Isofol Medical AB (publ). It explicitly mentions 'Reason for major shareholding notification Sell' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' holdings, including the resulting percentage (4.90568%). This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ' (Major Shareholding Notification). The document is short and appears to be the official filing itself, not an announcement of a report.
2022-07-28 English
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Isofol Medical AB (publ). It explicitly mentions 'Reason for major shareholding notification Sell', provides the 'Date' of the transaction (26/07/2022), and lists the resulting 'Total' percentage of voting rights (5.03598 %). This structure and content directly correspond to a notification regarding a change in significant share ownership, which maps to the Major Shareholding Notification category.
2022-07-27 English
Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2022
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämma i Isofol Medical AB (publ) den 19 maj 2022" (Communiqué from the Annual General Meeting in Isofol Medical AB (publ) on May 19, 2022). The content details the decisions made by the shareholders at the AGM, including the approval of financial statements, election of the board and auditor, decisions on remuneration, approval of the remuneration report, adoption of remuneration guidelines, and amendments to the articles of association. These are all core components of an Annual General Meeting outcome announcement. Therefore, the correct classification is AGM-R (AGM Information).
2022-05-19 Swedish
Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022
AGM Information Classification · 100% confidence The document explicitly states it is a "Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on May 19, 2022". It details the principal resolutions passed at the AGM, including the adoption of financial statements, election of board members and auditors, approval of remuneration reports, and amendments to articles of association. This content directly corresponds to the materials presented or finalized during an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2022-05-19 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-March 2022 for Isofol Medical AB. It contains comprehensive financial data, including income statements, balance sheet summaries, and key performance indicators (KPIs) for the quarter, as well as detailed management commentary on clinical trials (AGENT study), FDA interactions, and business strategy. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-12 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.